Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
Therapeutic advances in hematology(2023)
Abstract
NCT03328273.
MoreTranslated text
Key words
relapsed/refractory chronic lymphocytic leukemia,ceralasertib,acalabrutinib,monotherapy,high-risk
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined